Transparency of communication of the risk-benefit assessment: The example of medications;Communication et transparence de l'évaluation du risque et bénéfice en santé publique: Exemple du médicament

Therapie

Volumn , Issue 4, 2001, Pages 335-339

  Lehner, J P ^a   Meyer, F ^b   Juillet, Y ^c   Ancolio, C ^d   Ayme S ^d   Bader, J P ^d   Bouvenot, G ^d   Bouvier, E ^d   Caulin, C ^d   De Cremiers F ^d   Demarez, J P ^d   Debuscher, P O ^d   Dangoumau, J ^d   Danan, C ^d   David, N ^d   Giri, I ^d   Huderi, E ^d   Lagarde, D ^d   Lecam, Y ^d   Lenoir, P ^d   Maraninchi, D ^d   Marty, M ^d   Moachon Chauvelot, L ^d   Pichon, F ^d   Pigeon, M ^d   Ravilly, S ^d   Revnier, F ^d   Richot, C ^d   Sassard, J ^d   Veron, D ^d   Yahiel, M ^d   more..

^a SANOFI   (France)

^b AFSSAPS   (France)

^c Laboratoires Aventis France   (France)

^d NONE

Author keywords

Communication; Data; Interactions French Agency pharmaceutical companies; Interpretation; Validation

Indexed keywords

CONFERENCE PAPER; DATA ANALYSIS; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; FRANCE; INFORMATION SYSTEM; INTERNET; INTERPERSONAL COMMUNICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ARTICLE; CLINICAL TRIAL; CONSUMER; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HUMAN; MASS MEDIUM; ORGANIZATION; PATIENT EDUCATION; RISK ASSESSMENT; STANDARD;

DRUG;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; CONGRESSES; CONSUMER SATISFACTION; DISCLOSURE; DRUG EVALUATION; DRUG INDUSTRY; DRUG INFORMATION SERVICES; FRANCE; HUMANS; INTERNET; MASS MEDIA; PATIENT EDUCATION; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 0034741195     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)